Literature DB >> 10390549

Neurotrophic factors regulate cathepsin S in macrophages and microglia: A role in the degradation of myelin basic protein and amyloid beta peptide.

J P Liuzzo1, S S Petanceska, L A Devi.   

Abstract

BACKGROUND: Cathepsin S is a member of the family of cysteine lysosomal proteases preferentially expressed in macrophages and microglia and is active after prolonged incubation in neutral pH. Upon activation of macrophages by a number of inflammatory mediators, there is an increase in secreted cathepsin S activity accompanied by a decrease in cellular cathepsin S activity and protein content, as well as a decrease in cathepsin S mRNA. The decrease in cathepsin S mRNA and protein at the cellular level is in contrast to the response observed in some in vivo scenarios.
MATERIALS AND METHODS: We investigated the effect of basic fibroblast growth factor (bFGF) and nerve growth factor (NGF), two growth factors present during cell injury and inflammation but not known to activate macrophages and microglia, on the expression of cathepsin S, cathepsin B, and cathepsin L mRNAs in these cells, and on cathepsin S activity. We then tested the ability of cathepsin S to degrade myelin basic protein, and amyloid beta peptide at both acidic and neutral pH.
RESULTS: Basic FGF and NGF treatment of macrophages and microglia significantly increased the levels of cathepsin S, B, and L mRNAs (2- to 5-fold). Basic FGF also increased cathepsin S activity intra- and extracellularly. Recombinant human cathepsin S was able to degrade myelin basic protein and monomeric and dimeric amyloid beta peptide at both acidic and neutral pH, as well as to process human amyloid precursor protein generating amyloidogenic fragments.
CONCLUSIONS: These data suggest that bFGF and NGF may be the molecular signals that positively regulate the expression and activity of cysteine lysosomal proteases (cathepsin S in particular) in macrophages and microglia in vivo, and that there is an interplay between these factors and the activators of inflammation. Disruption of the balance between these two categories of signals may underlie the pathological changes that involve cysteine proteases. http://link.springer-ny.com/link/service/journals/00020/bibs /5n5p334. html

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390549      PMCID: PMC2230424     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  41 in total

1.  Basic FGF in astroglial, microglial, and neuronal cultures: characterization of binding sites and modulation of release by lymphokines and trophic factors.

Authors:  D M Araujo; C W Cotman
Journal:  J Neurosci       Date:  1992-05       Impact factor: 6.167

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Fibroblast growth factors: potential neurotrophic agents in the central nervous system.

Authors:  R S Morrison
Journal:  J Neurosci Res       Date:  1987       Impact factor: 4.164

4.  Pentapeptide (pepstatin) inhibition of brain acid proteinase.

Authors:  N Marks; A Grynbaum; A Lajtha
Journal:  Science       Date:  1973-09-07       Impact factor: 47.728

5.  Regulation of the transcript for a lysosomal protein: evidence for a gene program modified by platelet-derived growth factor.

Authors:  K K Frick; P J Doherty; M M Gottesman; C D Scher
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

6.  Cloning and characterization of a mouse cysteine proteinase.

Authors:  D A Portnoy; A H Erickson; J Kochan; J V Ravetch; J C Unkeless
Journal:  J Biol Chem       Date:  1986-11-05       Impact factor: 5.157

Review 7.  The cell biology of macrophage activation.

Authors:  D O Adams; T A Hamilton
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

8.  Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH.

Authors:  M Nilsen-Hamilton; R T Hamilton; W R Allen; S L Massoglia
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

9.  The macrophage as an effector cell.

Authors:  C F Nathan; H W Murray; Z A Cohn
Journal:  N Engl J Med       Date:  1980-09-11       Impact factor: 91.245

10.  Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA.

Authors:  M M Gottesman; M E Sobel
Journal:  Cell       Date:  1980-02       Impact factor: 41.582

View more
  19 in total

Review 1.  Neurotrophins and the immune system.

Authors:  José A Vega; Olivia García-Suárez; Jonas Hannestad; Marta Pérez-Pérez; Antonino Germanà
Journal:  J Anat       Date:  2003-07       Impact factor: 2.610

2.  Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice.

Authors:  Fiore Cattaruzza; Victoria Lyo; Ella Jones; David Pham; James Hawkins; Kimberley Kirkwood; Eduardo Valdez-Morales; Charles Ibeakanma; Stephen J Vanner; Matthew Bogyo; Nigel W Bunnett
Journal:  Gastroenterology       Date:  2011-07-28       Impact factor: 22.682

Review 3.  Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats.

Authors:  Young S Gwak; Jonghoon Kang; Geda C Unabia; Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2011-10-21       Impact factor: 5.330

4.  The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling.

Authors:  Desmond J Tobin; Kerstin Foitzik; Thomas Reinheckel; Lars Mecklenburg; Vladimir A Botchkarev; Christoph Peters; Ralf Paus
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Active cathepsins B, L, and S in murine and human pancreatitis.

Authors:  Victoria Lyo; Fiore Cattaruzza; Tyson N Kim; Austin W Walker; Margot Paulick; Daniel Cox; Jordan Cloyd; James Buxbaum; James Ostroff; Matthew Bogyo; Eileen F Grady; Nigel W Bunnett; Kimberly S Kirkwood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-16       Impact factor: 4.052

6.  Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity.

Authors:  A J Slavin; J M Soos; O Stuve; J C Patarroyo; H L Weiner; A Fontana; E K Bikoff; S S Zamvil
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 7.  Cysteine cathepsins in neurological disorders.

Authors:  Anja Pišlar; Janko Kos
Journal:  Mol Neurobiol       Date:  2013-11-15       Impact factor: 5.590

Review 8.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

9.  The clinical significance of cathepsin S expression in human astrocytomas.

Authors:  Thomas Flannery; David Gibson; Menakshi Mirakhur; Stephen McQuaid; Caroline Greenan; Anne Trimble; Brian Walker; Derek McCormick; Patrick G Johnston
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

10.  Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain.

Authors:  Anna K Clark; Ping K Yip; John Grist; Clive Gentry; Amelia A Staniland; Fabien Marchand; Maliheh Dehvari; Glen Wotherspoon; Janet Winter; Jakir Ullah; Stuart Bevan; Marzia Malcangio
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.